Tag Archives: Rituximab Biosimilars Market Size

The biosimilars market, particularly in the context of rituximab, is experiencing a dynamic shift in the global healthcare landscape. Rituximab, originally developed as a biologic drug for the treatment of cancers like non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL), as well as autoimmune diseases like rheumatoid arthritis (RA), has …

Read More »